A COMPARISON OF SERUM NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 IN DIABETIC AND NON-DIABETIC PATIENTS WITH OSTEOARTHRITIS
DOI:
https://doi.org/10.55519/JAMC-02-13742Keywords:
Nuclear factor erythroid 2-related factor 2 (Nrf2), oxidative stress, antioxidantsAbstract
Background: Osteoarthritis (OA) or inflammation of joints is a chronic degenerative and irreversible joint disorder. Oxidative stress in chronic inflammation contributes to osteoarthritis. Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway have an inhibitory role in oxidative stress and inflammation, as significant interaction exists between transcriptional pathways involving Nrf2 and NF-κB which is related to immune response in body. Diabetes mellitus being a pro inflammatory condition, has more oxidative damage due to the effects of hyperglycaemia. This study evaluated serum Nrf2 expression levels in osteoarthritis patients in the presence and absence of hyperglycaemia in order to find out the magnitude of anti-oxidative response, whether Nrf2 expression levels increases or decreases in oxidative stress environment comparatively. Objectives of this study were to evaluate Nrf2 serum expression levels in osteoarthritis patients by ELISA and to compare Nrf2 serum circulatory levels between diabetic osteoarthritis patients’ group and non-diabetic osteoarthritis patients’ group. Method: The comparative cross-sectional study was conducted from February 01, 2023 to 31 January, 2024 at department of Biochemistry, Nowshera medical college (NMC), Nowshera and Medicine/Orthopaedic OPD of Qazi Husain Ahmad Medical complex (QHAMC), Nowshera. This comparative cross-sectional study included 44 male and female osteoarthritis patients of ≥50 years old that were further divided into a diabetic and non-diabetic group on the basis of hyperglycaemia. NRF2 levels were measured using ELISA. Results: Blood circulatory levels of NRF2 were significantly higher in non-diabetic patients of osteoarthritis Conclusion: Nrf2 levels are lower in diabetic patients of osteoarthritis as compared to non-diabetic patients of osteoarthritis.
References
1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019;393(10182):1745–59.
2. Saha S, Rebouh NY. Anti-osteoarthritis mechanism of the Nrf2 signaling pathway. Biomedicines 2023;11(12):3176.
3. Taylor EL, Collins JA, Gopalakrishnan P, Chubinskaya S, Loeser RF. Age and oxidative stress regulate Nrf2 homeosta-sis in human articular chondrocytes. Osteoarthritis Cartilage 2023;31(9):1214–23.
4. Abusarah J, Shi Q, Fahmi H, Fernandes JC, Benderdour M. The role of NRF2 transcription factor in osteoarthritis. Oste-oarthritis Cartilage 2014;22(Suppl):S146.
5. Che J, Yang X, Jin Z, Xu C. Nrf2: A promising therapeutic target in bone-related diseases. Biomed Pharmacother 2023;168:115748.
6. Geiger BC, Wang S, Padera RF Jr, Grodzinsky AJ, Hammond PT. Cartilage-penetrating nanocarriers improve delivery and efficacy of growth factor treatment of osteoarthritis. Sci Transl Med 2018;10(469):eaat8800.
7. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from ESCEO. Semin Ar-thritis Rheum 2019;49(3):337–50.
8. Sokolove J, Lepus CM. Role of inflammation in the patho-genesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 2013;5(2):77–94.
9. Sireesh D, Dhamodharan U, Ezhilarasi K, Vijay V, Ramkumar KM. Association of Nrf2 and inflammatory cytokines in Type 2 Diabetes Mellitus. Sci Rep 2018;8(1):1–10.
10. Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic Biol Med 2019;132:73–82.
11. Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med 2016;59(5–6):333–9.
12. Wu J, Zhang XY, Hu SQ, Pan SH, Wang CL. Polygonatum sibiricum polysaccharide inhibits IL-1β-induced inflamma-tion in chondrocytes. Food Sci Technol 2022;42:e40421.
13. Chen B, Deng Y, Tan Y, Qin J, Chen LB. Interleukin 17 and knee osteoarthritis severity. J Int Med Res 2014;42(1):138–44.
14. Ansari MY, Khan NM, Ahmad I, Haqqi TM. Parkin regulates ROS and survival of human chondrocytes. Osteoarthritis Car-tilage 2018;26(8):1087–97.
15. Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H. Functional domains of ADAMTS-4 and ADAMTS-5. J Biol Chem 2008;283(10):6706–16.
16. Thomas DPP, King B, Stephens T, Dingle JT. Cartilage re-generation after catabolin/IL-1 damage. Ann Rheum Dis 1991;50(2):75–80.
17. Khan NM, Haseeb A, Ansari MY, Devarapalli P, Haynie S, Haqqi TM. Wogonin, a plant derived small molecule, exerts potent anti-inflammatory and chondroprotective effects through the activation of ROS/ERK/Nrf2 signaling pathways in human Osteoarthritis chondrocytes. Free Radic Biol Med. 2017;106:288–301.
18. Ko JY, Choi YJ, Jeong GJ, Im GI. Sulforaphane-PLGA micro-spheres for osteoarthritis. Biomaterials 2013;34(21):5359–68.
19. Koike M, Nojiri H, Ozawa Y, Watanabe K, Muramatsu Y, Kaneko H, et al. Mechanical overloading and oxidative stress in cartilage. Sci Rep 2015;5:11722.
20. Wu Z, Yang Z, Liu L, Xiao Y. Natural compounds and NRF2/ARE signaling in OA. Front Pharmacol 2023;14:1188215.
21. Siewert S, González I, Santillán LD, Lucero R, Ojeda MS, Gimenez MS. Downregulation of Nrf2 and HO-1 expression contributes to oxidative stress in type 2 diabetes mellitus: A study in Juana Koslay City, San Luis, Argentina. J Diabetes Mellitus 2013;3(2):71–8.
22. Jiménez-Osorio AS, Picazo A, González-Reyes S, et al. Nrf2 and redox status in diabetic patients. Int J Mol Sci 2014;15(11):20290–305.
23. Khan NM, Ahmad I, Haqqi TM. Nrf2/ARE pathway activates ERK1/2 and protects OA chondrocytes. Free Radic Biol Med 2018;116:159–71.
24. Neilson LE, Quinn JF, Gray NE. NRF2 as a biomarker in human health. Antioxidants 2021;10(1):28.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zahid Irfan Marwat, Alamzeb Jadoon, Shah Nawaz, Aamir Sheharyar, Saifoor Ahmad Khan, Muhammad Israr
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
